Facility
Offering full end-to-end manufacturing capabilities
The Biologics Manufacturing Centre’s two-level building facility with a total area of approximately 54 900 square feet (ft2), is equipped with end-to-end production capability for vaccines and cell-based biopharmaceuticals from mammalian and insect cell cultures for human use.
It has the production capacity for drug substance, fill-finishing, visual inspection, labelling, packaging, and warehousing, including testing.
The HVAC systems are designed to control the filtration for airborne particulate and microbial bioburden based on GMP requirements, and biosafety containment level requisites.
The BMC is designed to treat the local supply of potable water to produce purified water (PW) meeting current USP and EP monographs. The PW feeds the Water for Injection (WFI) system meeting the current USP and EP monograph with a production capacity of 1200 LPH.
There are no cytotoxic, highly potent or sensitizing agents handled on site.
Production Suites
Upstream
The upstream biomanufacturing process is the initial stage of the production where cells are gradually expanded from flasks to bioreactors. Initial cell culture manipulations are performed by Technologists in biosafety cabinets (BSC) and then, transferred to bioreactors.
The BMC bioreactor capacity totals 2,500 litres with one train up to 2000L and a second train up to 500L and supporting expansion bioreactors of 50L and 200L with flexibility embedded into its physical config- uration for future increase in production capacity.
Harvesting the product is performed through centrifugation and filtration, followed by clarification steps to further harvest the cell lysate or broth to remove any remaining cellular debris or particles.
Downstream
The downstream process involves the isolation of the desired product.
The specific methods and equipment used can vary depending on the nature of the cells, the product, and the process requirements.
Product recovery and purification steps can be performed through tangential flow filtration (ultrafiltra- tion/diafiltration / buffer exchange) chromatography columns, and/or steps to concentrate and purify the product. The equipment train can be tailored to suit your process and scale requirements for opti- mizing the yield, purity, and quality of your product.
Fill & Finish and Secondary Packaging
Once the bulk drug substance has been manufactured, it is transported to the filling suite, where it is formulated and filled into sterile vials using specialized filling equipment.
For glass vial filling BMC uses a closed isolator equipment from VanRx and container volumes can range from 2mL to 10mL.
Each vial is then carefully inspected in inspection booths, then labeled and packaged in their desired packaging format in the packaging area, and finally stored in the warehouse, in temperature-controlled areas as per required specifications, until they can be shipped to their next destination.
Quality Control Laboratory
Analytical Laboratory
Microbiology Laboratory
Utilities
Supply Chain & Warehouse
The 8,400 square foot warehouse within the BMC, is used to receive and store all the consumables and raw materials required to both maintain the facility in a continuous GMP readiness state and support client production.